Novartis Ag (NVS) EBT Margin (2009 - 2026)

Novartis Ag has disclosed EBT Margin across 18 years of filings, most recently posting 29.63% for Q2 2026.

• In Q2 2026, EBT Margin fell 261.0% year-over-year to 29.63%; the TTM figure through Jun 2026 stood at 30.91% (up 156.0% YoY), while the FY2025 annual figure was 29.99%, up 288.0% from the prior year.
• EBT Margin came in at 29.63% for Q2 2026 at Novartis Ag, up from 29.28% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 33.3% in Q1 2025 to a low of 13.17% in Q3 2023.
• Average EBT Margin over 5 years is 24.92%, with a median of 26.42% recorded in 2024.
• Year-over-year, EBT Margin plunged 4909 bps in 2022 and jumped 1323 bps in 2024.
• Over 5 years, EBT Margin stood at 17.73% in 2022, then gained by 12 bps to 19.83% in 2023, then soared by 41 bps to 27.86% in 2024, then increased by 18 bps to 32.76% in 2025, then retreated by 10 bps to 29.63% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 29.63% in Q2 2026, 29.28% in Q1 2026, and 32.76% in Q4 2025.